While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the best CRISPR stocks to buy. On June 24, Thermo Fisher Scientific Inc. (NYSE:TMO) partnered with Xcell Biosciences, an instrumentation firm ...

US FDA eliminates REMS for autologous chimeric antigen receptor CAR T cell immunotherapies: Maryland Monday, June 30, 2025, 13:00 Hrs [IST] The US Food and Drug Administration (FD ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

Researchers at the University of California Davis Comprehensive Cancer Center have uncovered an evolutionary change that may ...

Researchers have pioneered a novel 3D platform that mimics the human bone marrow and immune environment, enabling more ...

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...